Discovery of TYRA-300: First Oral Selective FGFR3 Inhibitor for the Treatment of Urothelial Cancers and Achondroplasia

Robert L. Hudkins(State Street (United States)), Daniel C. Bensen(State Street (United States)), Isaac Hoffman(Electronic BioSciences (United States)), Kirk Nelson(Arcturus Therapeutics (United States)), Alexandra Balcer(State Street (United States)), Melissa Neal(State Street (United States)), Ronald V. Swanson(Diversitech (United States)), Qing Ye(State Street (United States)), Piyush Patel(State Street (United States)), Todd J. Harris(State Street (United States)), Marc Rideout(State Street (United States)), Samhita Iyer(State Street (United States)), Eric Allen(State Street (United States)), Jacqueline H. Starrett(State Street (United States))
Journal of Medicinal Chemistry
September 11, 2024
10.1021/acs.jmedchem.4c01531
Cited by 28

Related Papers

The complete genome of the hyperthermophilic bacterium Aquifex aeolicus
|Nature|1998|1.1k
Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery
|ACS Chemical Neuroscience|2011|436
Comparative Genomic Analysis of Archaeal Genotypic Variants in a Single Population and in Two Different Oceanic Provinces
|Applied and Environmental Microbiology|2002|171
CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
|PubMed|2003|124
Neurotrophic 3,9-Bis[(alkylthio)methyl]- and -Bis(alkoxymethyl)-K-252a Derivatives
|Journal of Medicinal Chemistry|1997|120